Trial Profile

A Phase I Clinical Trial of Epidermicin NI01

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epidermicin NI01 (Primary)
Indications Methicillin-resistant Staphylococcus aureus infections; Skin infections; Wound infections
Focus Adverse reactions

15 Feb 2019 New trial record
05 Feb 2019 According to an Igenza media release, University of Plymouth spin-out Amprologix (in which Ingenza has a stake) has been awarded a 1.2 million pound contract from the UK Department of Health and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01.The funding, administered by Innovate UK, is intended to advance Epidermicin NI01.This study expected to start by early 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com